Boston Scientific (NYSE:BSX) Price Target Cut to $100.00 by Analysts at Oppenheimer

Boston Scientific (NYSE:BSX) had its price objective lowered by Oppenheimer from $125.00 to $100.00 in a research note released on Friday, Marketbeat Ratings reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

Other analysts also recently issued reports about the company. Evercore ISI set a $112.00 price target on Boston Scientific in a research note on Monday, January 5th. UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Friday, November 21st. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $123.89.

Boston Scientific Price Performance

Shares of BSX opened at $88.13 on Friday. The company’s 50-day moving average is $96.90 and its 200-day moving average is $100.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm has a market capitalization of $130.65 billion, a PE ratio of 47.13, a PEG ratio of 1.59 and a beta of 0.67. Boston Scientific has a fifty-two week low of $85.98 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Pallas Capital Advisors LLC grew its position in Boston Scientific by 52.9% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,163 shares of the medical equipment provider’s stock worth $662,000 after acquiring an additional 2,132 shares during the last quarter. Secure Asset Management LLC increased its holdings in Boston Scientific by 36.1% in the 2nd quarter. Secure Asset Management LLC now owns 5,642 shares of the medical equipment provider’s stock worth $606,000 after purchasing an additional 1,496 shares in the last quarter. Atticus Wealth Management LLC bought a new position in Boston Scientific in the second quarter valued at about $193,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Boston Scientific by 279.0% during the second quarter. Exchange Traded Concepts LLC now owns 41,872 shares of the medical equipment provider’s stock valued at $4,497,000 after purchasing an additional 30,824 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.